Your browser doesn't support javascript.
loading
Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro.
Rombach-Riegraf, Verena; Karle, Anette C; Wolf, Babette; Sordé, Laetitia; Koepke, Stephan; Gottlieb, Sascha; Krieg, Jennifer; Djidja, Marie-Claude; Baban, Aida; Spindeldreher, Sebastian; Koulov, Atanas V; Kiessling, Andrea.
Afiliación
  • Rombach-Riegraf V; Novartis Pharma AG, Technical R&D, Biologics Process R&D, Late Phase Analytical & Pharmaceutical Development, Werk Klybeck, Basel, Switzerland.
  • Karle AC; Novartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland.
  • Wolf B; Novartis Pharma AG, Pre-clinical Safety, Biologics Safety and Disposition, Experimental Pathology, Immunosafety, Werk Klybeck, Basel, Switzerland.
  • Sordé L; Novartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland.
  • Koepke S; Novartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland.
  • Gottlieb S; Novartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland.
  • Krieg J; Novartis Pharma AG, Pre-clinical Safety, Biologics Safety and Disposition, Experimental Pathology, Immunosafety, Werk Klybeck, Basel, Switzerland.
  • Djidja MC; Novartis Pharma AG, Technical R&D, Biologics Process R&D, Late Phase Analytical & Pharmaceutical Development, Werk Klybeck, Basel, Switzerland.
  • Baban A; Novartis Pharma AG, Pre-clinical Safety Biologics Safety and Disposition, Bioanalytics, Werk Klybeck, Basel, Switzerland.
  • Spindeldreher S; Novartis Pharma AG, Pre-clinical Safety Biologics Safety and Disposition, Bioanalytics, Werk Klybeck, Basel, Switzerland.
  • Koulov AV; Novartis Pharma AG, Technical R&D, Biologics Process R&D, Late Phase Analytical & Pharmaceutical Development, Werk Klybeck, Basel, Switzerland.
  • Kiessling A; Novartis Pharma AG, Pre-clinical Safety, Biologics Safety and Disposition, Experimental Pathology, Immunosafety, Werk Klybeck, Basel, Switzerland.
PLoS One ; 9(1): e86322, 2014.
Article en En | MEDLINE | ID: mdl-24466023
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Dendríticas / Proteínas Recombinantes / Linfocitos T CD4-Positivos / Anticuerpos Monoclonales Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2014 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Dendríticas / Proteínas Recombinantes / Linfocitos T CD4-Positivos / Anticuerpos Monoclonales Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2014 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos